Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
| 适应症 | Pancreatic Cancer |
|---|---|
| 分期 | 2期 |
| 申办方 | Massachusetts General Hospital |
| 状态 | 已完成 |
| 受试者人数 | 50 人 |
| 干预（药物） | Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy |
| 开始日期 | 2011年12月27日 |
| 完成日期 | 2018年9月16日 |
| 结果公布日 | 2026年8月5日 |
摘要
A standard treatment for patients with pancreatic cancer is standard photon radiation in combination with the chemotherapy drug, capecitabine. In this research study the investigators are using standard photon radiation or a different type of radiation therapy called proton beam radiation and adding hydroxychloroquine to be used in combination with capecitabine. In this research study, the investigators are looking to determine if proton or photon beam radiation in combination with hydroxychloroquine and capecitabine is effective in controlling your cancer growth.
Progression-free Survival
| Hydroxychloroquine | 16 Participants |
|---|---|
| Hydroxychloroquine | 10 Participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — XBiotech, Inc.
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanc — National Cancer Institute (NCI)
- Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to t — National Cancer Institute (NCI)
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poo — ECOG-ACRIN Cancer Research Group
- A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) — University of Iowa